[1]吴泽刚,李 艳,郑红云,等.恶性肿瘤患者UGT1A1基因启动子多态性检测结果分析[J].现代检验医学杂志,2015,30(03):35-37.[doi:10.3969/j.issn.1671-7414.2015.03.010]
　WU Ze-gang,LI Yan,ZHENG Hong-yun,et al.Analysis on Gene Polymorphism of UGT1A1 Gene Promoter in Patients with Malignant Tumour[J].Journal of Modern Laboratory Medicine,2015,30(03):35-37.[doi:10.3969/j.issn.1671-7414.2015.03.010]
点击复制

恶性肿瘤患者UGT1A1基因启动子多态性检测结果分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年03期
页码:
35-37
栏目:
论著
出版日期:
2015-06-10

文章信息/Info

Title:
Analysis on Gene Polymorphism of UGT1A1 Gene Promoter in Patients with Malignant Tumour
文章编号:
1671-7414(2015)03-035-04
作者:
吴泽刚; 李 艳; 郑红云; 熊 格
武汉大学人民医院检验科,武汉 430060
Author(s):
WU Ze-gang; LI Yan; ZHENG Hong-yun; XIONG Ge
Department of Clinical Laboratory, Renmin Hospital of Wuhan University,Wuhan 430060,China
关键词:
UGT1A1基因;  基因测序;  多态性;  伊立替康
分类号:
R730.43
DOI:
10.3969/j.issn.1671-7414.2015.03.010
文献标志码:
A
摘要:
目的 应用基因测序技术检测分析UGT1A1基因启动子多态性特点,并探讨UGT1A1*28和UGT1A1*6基因多态性在武汉地区的分布。方法 收集2013年1月～2014年12月武汉大学人民医院肿瘤内科230例肿瘤患者外周血,通过Sanger测序法测定靶片段的基因序列,分析患者UGT1A1基因启动子区TA盒多态性。结果 研究检测的230例肿瘤患者中,TA6/TA6野生型198例(86.1%),TA6/TA7杂合型29例(12.6%),TA7/TA7变异型3例(1.3%)。结论 武汉地区恶性肿瘤患者UGT1A1基因TA6/TA6野生型最常见。
Abstract:
Objective To detect UGT1A1 gene promoter polymorphism with gene sequence method and analyze the distribution of UGT1A1*28 and UGT1A1*6 gene polymorphism in Wuhan.Methods A total of 230 samples were collected from tumor patient in Medical Oncology Department of Renmin Hospital of Wuhan University from January 2013 to December 2014,then genesequence of the target fragments were detected by Sanger sequencing method and analyzed patient UGT1A1 gene promoter polymorphism TA box.Results In this research examination 230 example tumor patient,198 patients(86.1%)were identified with TA6/TA6 genotype,29 patients(12.6%)were identified with TA6/TA7 genotype,3 patients(1.3%)TA7/TA7 variant.Conclusion TA6/TA6 wild-typewas higher frequence in patients with malignant tumour in Wuhan.

参考文献/References:

[1] Salz LB,Cox JV,Blanke C,et al.Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.Irinotecan Study Group[J].N Engl J Med,2000,343(13):905-914.
[2] Zhe YH,Qi Y,Qi P,et al.Dose-dependent association between UGTlAl*28genotype and irinotecan-induced neutropenia:low doses also inerease risk[J].Clin Cancer Res,2010,16(15):3832-3842.
[3] Marcuello E, A1tes A, Menoyo A,et al.UGT1A1 gene variations and irinotecan treatment in patients with metastatic colon rectal cancer[J].Br J Cancer,2004,91(4):678-682.
[4] 王 晖,武晓楠,丁 丽,等.伊立替康相关不良反应与UGT1A1基因多态性的关系[J].现代肿瘤医学,2013,21(1):161-163.
Wang H,Wu XN,Ding L,et al.The association of irinotecan relatedadverse effects and UGT1A1 gene polymorphism[J].Journal of Modern Oncology,2013,21(1):161-163.
[5] 陈志威,苏大芝,曹 勤,等.尿苷二磷酸葡萄糖醛酸转移酶1A1基因常见多态性位点的分布[J].中华消化杂志,2014,34(5):311-315.
Chen ZW,Su DZ,Cao Q,et al.Distribution of common polymorphic loci of gene uridine diphosphate-glucuronosyltransferase 1A1[J].Chinese Journalof Digestion,2014,34(5):311-315.
[6] 徐建明.尿苷二磷酸葡萄糖苷转移酶1A1与伊立替康相关毒性的关系[J].中华肿瘤杂志,2013,35(4):241-243.
Xu JM.Study of irinotecan-induced toxicity and its correlation toUGT1A1[J].Chinese Journal of Oncology,2013,35(4):241-243.
[7] 李 虎,黄 鹤,刘继红.UGT1A1基因启动子多态性与伊立替康化疗毒性作用的关系[J].中华妇产科杂志,2011,46(12):888-891.
Li H,Huang H,Liu JH.Study of irinotecan-induced toxicity and itscorre lation to UGT1A1 gene promoter polymorphisms[J].Chinese Journal of Obstetrics and Gynecology,2011,46(12):888-891.
[8] Wang J,Fang LJ,Li L,et al.A new frame-shifting mutation of UGT1A1 gene causes type I Crigler-Najjar syndrome[J].Chinese Medical Journal,2011,124(23):4109-4111.
[9] Schulz C,Heinemann V,Schalhorn A,et al.UGT1A1 gene polymorphism:impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer[J].World J Gastroenterol,2009,15(40):5058-5066.
[10] 陈群蓉,孙顺昌,彭运生,等.UGT1A1基因启动子区A(TA)nTAA多态性分析及其与血清胆红素关系[J].诊断学理论与实践,2012,11(2):149-152.
Chen QR,Sun SC,Peng YS,et al.Polymorphism of A(TA)n TATAA in promoterregion of UGT1A1 gene and its correlation with serum bilirubin[J].Journal of Diagnostics Concepts & Practice,2012,11(2):149-152.
[11] Cai X,Cao WG,Ding HH,et al.Analysis of UGT 1A1*28 genotypeand SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients withadvanced colorectal cancer:results from a multicenter,retrospective study in Shanghai[J].J Cancer Res Clin Oncol,2013,139(9):1579-1589.
[12] Ribrag V,Koscielny S,Casasnovas O,et al.Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis[J].Blood,2009,113(14):3307-3313.
[13] 张 勇,苏 丹,郭晓川,等.UGT1A1*28和UG-T1A1*6基因多态性与伊立替康不良反应的关系[J].解放军医学院学报,2014,35(5):489-492,495.
Zhang Y,Su D,Guo XC,et al.Relationship between UGT1A1*28 and UGT1A1*6gene polymorphism and adverse reactions of irinotecan-based chemotherapy[J].Academic Journal of Chinese PLA Medical School,2014,35(5):489-492,495.
[14] Strassburg CP.Hyperbilirubinemia syndromes(Gi-lbert-Meulengracht,Crigler-Najjar,Dubin Johnson,and Rotor syndrome)[J].Best Pract Res Clin Gastroenterol,2010,24(5):555-571.

相似文献/References:

[1]吴泽刚,李 艳,郑红云.湖北地区慢性丙型肝炎患者HCV基因分型结果分析[J].现代检验医学杂志,2016,31(01):38.[doi:10.3969/j.issn.1671-7414.2016.01.010]
　WU Ze-gang,LI Yan,ZHENG Hong-yun.Analysis on HCV Genotype of Patients with Chronic Hepatitis C inHubei[J].Journal of Modern Laboratory Medicine,2016,31(03):38.[doi:10.3969/j.issn.1671-7414.2016.01.010]
[2]刘万静,王多春,唐 倩.血清凝集、基因测序联合检测群霍乱弧菌的应用[J].现代检验医学杂志,2015,30(02):84.[doi:10.3969/j.issn.1671-7414.2015.02.026]
　LIU Wan-jing,WANG Duo-chun,TANG Qian.Application of Detecting Vibrio Cholerae Combined with Serum Agglutination and Gene Sequencing[J].Journal of Modern Laboratory Medicine,2015,30(03):84.[doi:10.3969/j.issn.1671-7414.2015.02.026]
[3]吴 意,金 娴,樊春卉,等.单管双重巢式聚合酶链反应及基因测序技术鉴别呼吸道合胞病毒A,B亚型[J].现代检验医学杂志,2018,33(01):44.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　WU Yi,JIN Xian,FAN Chun-hui,et al.Identification of Respiratory Syncytial Virus A and B SubtypesbyTube Double Nested Polymerase Chain Reaction and Gene Sequencing Technology[J].Journal of Modern Laboratory Medicine,2018,33(03):44.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[4]李 君,曹立瀛,侯金友,等.河北省唐山地区人群红细胞A2B亚型分布情况及其分子机制的研究[J].现代检验医学杂志,2019,34(02):20.[doi:10.3969/j.issn.1671-7414.2019.02.006]
　LI Jun,CAO Li-ying,HOU Jin-you,et al.Study on Distribution and Molecular Mechanism of A2B SubtypeIndividuals in Tangshan Region of Hebei Province[J].Journal of Modern Laboratory Medicine,2019,34(03):20.[doi:10.3969/j.issn.1671-7414.2019.02.006]

备注/Memo

备注/Memo:
基金项目:国家临床重点专科建设项目(财社[2010]305号)。
作者简介:吴泽刚(1985-),男,硕士,医师,研究方向为感染性疾病的分子诊断,E-mail:wuzegang1234@163.com。
通讯作者:李 艳,E-mail: yantfl120@163.com。
更新日期/Last Update: 2015-06-10